Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18593842 | INJECTABLE PHOTOTHERMAL HYDROGEL BASED ON MELANIN, PREPARATION METHOD, AND APPLICATION THEREOF | March 2024 | June 2024 | Allow | 4 | 0 | 1 | No | No |
| 18407400 | SHP2 INHIBITOR AND USE THEREOF | January 2024 | March 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18367635 | (6-METHYL-4-SUBSTITUTEDPHENYL-2-OXO/THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN- 5-YL)(PIPERIDIN-1-YL)METHANONES AS ANTITUBERCULAR AGENTS | September 2023 | March 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18460080 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | September 2023 | January 2024 | Allow | 4 | 1 | 0 | No | No |
| 18456385 | CRYSTALLIZED FORM OF LURBINECTEDIN AND METHOD OF MAKING THE SAME | August 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18238427 | PYRIDO[3,4-B]INDOLE-6-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | August 2023 | January 2024 | Allow | 5 | 2 | 0 | Yes | No |
| 18364074 | HDAC INHIBITOR SOLID STATE FORMS | August 2023 | March 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18354467 | Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds | July 2023 | December 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18328392 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | June 2023 | October 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18315278 | IRAK DEGRADERS AND USES THEREOF | May 2023 | March 2024 | Abandon | 10 | 0 | 1 | Yes | No |
| 18029869 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | March 2023 | October 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 18192735 | GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF | March 2023 | August 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18147172 | Acyclic Thiol Prodrugs | December 2022 | February 2024 | Allow | 14 | 1 | 1 | No | No |
| 18002217 | ANTIVIRAL THERAPY WITH IMIQUIMOD AND COCRYSTALS THEREOF | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18002221 | IMIQUIMOD COCRYSTALS | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18080570 | HDAC INHIBITOR SOLID STATE FORMS | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17906212 | CRYSTALLINE PSILACETIN DERIVATIVES | September 2022 | April 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 17877476 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | July 2022 | May 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17696926 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | March 2022 | June 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17693759 | Pyrazolopyridine Derivatives and Uses thereof | March 2022 | May 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 17688603 | MOCETINOSTAT IN COMBINATION WITH CHEMOTHERAPY TO TREAT RHABDOMYOSARCOMA | March 2022 | September 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17668649 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | February 2022 | July 2023 | Allow | 17 | 0 | 1 | No | No |
| 17568991 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | January 2022 | April 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17540657 | METHODS OF TREATING NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY USING MODIFIED FORMS OF TRIMETAZIDINE | December 2021 | April 2023 | Allow | 16 | 1 | 1 | No | No |
| 17456695 | CANNABICHROMENE-O-ACETATE SYNTHESIS, COMPOSITIONS, AND METHODS OF USE | November 2021 | July 2023 | Abandon | 19 | 1 | 0 | Yes | No |
| 17530300 | GLP-1R MODULATING COMPOUNDS | November 2021 | August 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17525248 | SEXUAL THERAPY FORMULATION AND METHOD OF TREATMENT | November 2021 | June 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17520173 | 2-PYRIDONES AND METHODS OF USE THEREOF | November 2021 | June 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17451739 | ENHANCED ACNE TREATMENT COMPOSITION | October 2021 | September 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17463731 | METHODS AND COMPOSITIONS OF SOLABEGRON FOR REDUCING BODY FAT | September 2021 | August 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17421821 | Compounds and Methods for Treating or Preventing Heart Failure | July 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17204774 | TREATING SARS-COV-2 INFECTED SUBJECTS WITH SMALL MOLECULE COMPOUNDS | March 2021 | September 2024 | Abandon | 42 | 3 | 1 | Yes | No |
| 17270377 | USE OF GABOXADOL IN THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND ASTHMA | February 2021 | May 2023 | Allow | 27 | 1 | 1 | No | No |
| 17180033 | METHOD FOR EXTRACTION OF CANNABINOIDS AND SYNTHESIS OF THC TO CBN | February 2021 | January 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17268632 | DENDRIMER FORMULATIONS | February 2021 | May 2024 | Allow | 39 | 1 | 0 | No | No |
| 17163206 | TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR | January 2021 | August 2023 | Allow | 31 | 1 | 1 | No | No |
| 17158867 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | January 2021 | September 2023 | Allow | 32 | 0 | 0 | No | No |
| 17260519 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | January 2021 | November 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17259472 | DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF | January 2021 | April 2024 | Allow | 39 | 3 | 1 | No | Yes |
| 17253968 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | December 2020 | August 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17104714 | Method for Stimulating Axonal Regeneration | November 2020 | February 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17047573 | DIELS-ALDER RING-OPENING PROCESS | October 2020 | November 2023 | Allow | 37 | 2 | 1 | No | No |
| 17045895 | PHARMACEUTICAL COMPOSITION OF NINTEDANIB ESYLATE | October 2020 | August 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17037164 | PRODUCTION METHOD OF MALEIMIDE | September 2020 | February 2024 | Allow | 40 | 1 | 0 | No | No |
| 17031301 | Cabazitaxel in mCRPC Patients Previously Treated with Docetaxel and Who Failed a Prior androgen signaling targeted inhibitor Agent | September 2020 | November 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16978918 | HETEROBIFUNCTIONAL COMPOUND HAVING MONODISPERSED POLYETHYLENE GLYCOL IN MAIN CHAIN AND SIDE CHAIN | September 2020 | June 2024 | Allow | 45 | 1 | 1 | No | No |
| 16975695 | EYE DROPS IN FORM OF SOLUTION COMPRISING BENZOPYRAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | August 2020 | August 2023 | Allow | 35 | 0 | 0 | No | No |
| 16970130 | Trialkyne Linking Agents and Methods of Use | August 2020 | April 2024 | Allow | 44 | 1 | 0 | No | No |
| 16966011 | METHOD FOR PREPARING DIALKYL CARBONATE BY ALCOHOLYSIS OF UREA | July 2020 | September 2023 | Allow | 38 | 1 | 1 | No | No |
| 16960700 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | July 2020 | July 2023 | Allow | 37 | 0 | 0 | Yes | No |
| 16497724 | NOVEL CRYSTAL FORMS OF A POL1 INHIBITOR | September 2019 | October 2023 | Allow | 49 | 1 | 0 | Yes | No |
| 16088096 | CRYSTALLINE FORMS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE HEMIHYDRATE | September 2018 | April 2023 | Allow | 55 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KUCHARCZK, JED A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KUCHARCZK, JED A works in Art Unit 1626 and has examined 50 patent applications in our dataset. With an allowance rate of 78.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner KUCHARCZK, JED A's allowance rate of 78.0% places them in the 38% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KUCHARCZK, JED A receive 0.94 office actions before reaching final disposition. This places the examiner in the 10% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by KUCHARCZK, JED A is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +18.3% benefit to allowance rate for applications examined by KUCHARCZK, JED A. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.